

Thermo Fisher offers animal origin-free formulation to support scaling of cell therapy manufacturing

15 April 2024 | News

Breakthrough medium delivers speed and scale to CAR-T cell therapy manufacturers



US-based Thermo Fisher Scientific Inc. has introduced the Gibco CTS OpTmizer One Serum-Free Medium (CTS OpTmizer One SFM), a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T-cell expansion. As a result, cell therapy manufacturers can use CTS OpTmizer One SFM to help optimise their workflows and get T-cell therapies to patients faster.

CTS OpTmizer One SFM's ready-to-use, one-part medium can help cell therapy manufacturers scale their manufacturing from process development to clinical trials and commercial manufacturing while maintaining consistent performance. As part of the cell expansion process, CTS OpTmizer One SFM delivers high cell viability, improved growth and maintains early memory T cell phenotype. In addition, the AOF formulation can help in mitigating risk by reducing opportunities for contamination or inconsistency due to animal-origin (AO) components.

The ability to more-rapidly expand less-differentiated T-cells to reach a desired dose can help manufacturers shorten the time to treatment, lower manufacturing costs, increase patient access, and enhance therapeutic efficacy.

OpTmizer One SFM's ready-to-use, one-part medium advances T-cell expansion and cell growth while helping cell therapy manufacturers improve overall drug function for both autologous and allogeneic therapies, when compared to other leading

AOF T-cell media.

CTS OpTmizer One SFM expands Thermo Fisher Scientific's Gibco Cell Therapy Systems (CTS) portfolio of products.